Johnson & Johnson $JNJ Shares Sold by United Asset Strategies Inc.

United Asset Strategies Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 59,142 shares of the company’s stock after selling 407 shares during the period. United Asset Strategies Inc.’s holdings in Johnson & Johnson were worth $9,034,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Nuveen LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $1,369,188,000. Pacer Advisors Inc. grew its holdings in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after purchasing an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. raised its holdings in Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after buying an additional 2,557,388 shares during the period. Kingstone Capital Partners Texas LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $401,420,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Johnson & Johnson by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock valued at $2,803,042,000 after acquiring an additional 2,129,612 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $193.76 on Wednesday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The stock has a 50 day moving average price of $184.79 and a 200 day moving average price of $169.31. The company has a market capitalization of $466.83 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Citigroup boosted their target price on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Argus set a $210.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Finally, Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.